0 Comment
In a significant breakthrough, researchers have unveiled a groundbreaking drug known as ‘Donanemab’, which shows immense promise in slowing down the progression of Alzheimer’s disease, a debilitating form of dementia that affects millions worldwide. Developed by pharmaceutical giant Eli Lilly, Donanemab targets the accumulation of amyloid protein plaques in the brains of individuals diagnosed with... Read More








